The Swiss Rockets mission is to deliver outstanding results for patients, inventors, and investors.
Founded in 2018 in Basel, Swiss Rockets is implementing a paradigm shift in healthcare. Cancer patients will benefit from new treatment therapies developed using innovative and disruptive methods. The Swiss Rockets team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine.
We aim to set new paradigms in healthcare. Disruptive innovation in everything we do will allow us to deliver breakthrough treatments to patients with cancer.
We conduct our business with the patients’ well-being in mind. Integrity, honesty, loyalty, and trust form the foundation on which we build our company and future success. All our investments, entrepreneurs, partners, and therapies always put the patients first.
Our passion for people and patients makes us go at speed and with the power of rockets.
Founded in 2018 in Basel, Swiss Rockets is implementing a paradigm shift in healthcare. Cancer patients will benefit from new treatment therapies developed using innovative and disruptive methods. The Swiss Rockets team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine.
We aim to set new paradigms in healthcare. Disruptive innovation in everything we do will allow us to deliver breakthrough treatments to patients with cancer.
We conduct our business with the patients’ well-being in mind. Integrity, honesty, loyalty, and trust form the foundation on which we build our company and future success. All our investments, entrepreneurs, partners, and therapies always put the patients first.
Our passion for people and patients makes us go at speed and with the power of rockets.
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Phone: +41 61 561 54 21
Founded date: 2018
Mentions in press and media 7
| Date | Title | Description |
| 14.03.2025 | Swiss Rockets obtains strategic investment | Rocketvax Ltd one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies. One of Rocketvax’s leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrat... |
| 25.01.2024 | Daniel Gutenberg amplifies his startup engagement with Swiss Rockets | With Daniel Gutenberg on its Board of Directors, Swiss Rockets, a catalyst for the success of biotech startups in the field of oncology, has won an experienced player in the startup scene to support their endeavours in creating the next ge... |
| 07.02.2023 | Fresh funds for RocketVax to accelerate second generation COVID-19 vaccines | |
| 30.01.2023 | Piqur assets sold to Swiss Rockets affiliate | |
| 12.11.2020 | ROCKETVAX launched to develop a next-generation SARS-CoV-2 vaccine | The rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for the biotech company Swiss Rockets AG, which is why it has acquired the DNA synthesis technology from the ETH Zurich spin-off Gigabases Switzerla... |
| 12.11.2020 | ROCKETVAX launched to develop a next-generation SARS-CoV-2 vaccine | |
| 27.11.2019 | Swiss Rockets reveals incubator business model for cancer research |